v3.26.3
Segment Reporting - Schedule of Significant Expense Categories (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Research and Development                
Total research and development $ 503,020   $ 146,901   $ 685,167 $ 316,605 $ 1,255,266 $ 2,103,366
General and Administrative                
Total general and administrative 3,285,481   489,325   3,988,926 861,071 2,512,470 1,917,154
Other Segment (Income) Expenses (16,493)   19,717   21,206 17,884 79,901 834,885
Net Loss 3,772,008 $ 923,291 655,943 $ 539,617 4,695,299 1,195,560 3,847,637 4,855,405
Personnel [Member]                
Research and Development                
Total research and development 265,815   137,609   428,599 280,233 1,158,074 1,793,458
General and Administrative                
Total general and administrative 244,065   116,922   390,905 189,049 1,084,329 510,396
Clinical and preclinical activities [Member]                
Research and Development                
Total research and development 230,875   5,662   246,608 29,112 82,016 262,833
Other [Member]                
Research and Development                
Total research and development 6,330   3,630   9,960 7,260 15,176 47,075
Professional services [Member]                
General and Administrative                
Total general and administrative 2,819,556   268,640   3,247,071 470,128 898,044 754,503
Corporate expenses [Member]                
General and Administrative                
Total general and administrative 182,260   66,262   274,333 126,794 378,341 499,017
Facility costs [Member]                
General and Administrative                
Total general and administrative $ 39,600   $ 37,501   $ 76,617 $ 75,100 $ 151,756 $ 153,238